Patents by Inventor Kelly J. McClure

Kelly J. McClure has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Flap modulators
    Patent number: 9073876
    Abstract: The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R1, L and R2 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: July 7, 2015
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Wendy Eccles, Anne E. Fitzgerald, Michael D. Hack, Natalie A. Hawryluk, William M. Jones, John M. Keith, Paul Krawczuk, Alec D. Lebsack, Jing Liu, Neelakandha S. Mani, Kelly J. McClure, Steven P. Meduna, Mark D. Rosen
  • FLAP MODULATORS
    Publication number: 20140221311
    Abstract: The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R1, R2, R3, R3?, L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I).
    Type: Application
    Filed: January 31, 2014
    Publication date: August 7, 2014
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Genesis M. Bacani, Wendy Eccles, Anne E. Fitzgerald, Steven D. Goldberg, Michael D. Hack, Natalie A. Hawryluk, William M. Jones, John M. Keith, Paul Krawczuk, Alec D. Lebsack, Alice Lee-Dutra, Jing Liu, Kelly J. McClure, Steven P. Meduna, Daniel J. Pippel, Mark D. Rosen, Zachary S. Sales
  • FLAP MODULATORS
    Publication number: 20140221310
    Abstract: The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R1, L and R2 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.
    Type: Application
    Filed: January 31, 2014
    Publication date: August 7, 2014
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Wendy Eccles, Anne E. Fitzgerald, Michael D. Hack, Natalie A. Hawryluk, William M. Jones, John M. Keith, Paul Krawczuk, Alec D. Lebsack, Jing Liu, Neelakandha S. Mani, Kelly J. McClure, Steven P. Meduna, Mark D. Rosen
  • TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1
    Publication number: 20140135311
    Abstract: Certain tetrahydro-pyrimidoazepine compounds are described, which are useful as TRPV1 modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by TRPV1. Thus, the compounds may be administered to treat, e.g., pain, itch, cough, asthma, or inflammatory bowel disease.
    Type: Application
    Filed: January 17, 2014
    Publication date: May 15, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Brett D. Allison, Bryan James Branstetter, J. Guy Breitenbucher, Michael D. Hack, Natalie A. Hawryluk, Alec D. Lebsack, Kelly J. McClure, Jeffrey E. Merit
  • Aryl-substituted bridged or fused diamines as modulators of leukotriene Ahydrolase
    Patent number: 8367719
    Abstract: Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: February 5, 2013
    Assignee: Janssen Pharmaceutica NV
    Inventors: Genesis M. Bacani, Scott D. Bembenek, Wendy Eccles, James P. Edwards, Laurent Gomez, Cheryl A. Grice, Aaron M. Kearney, Adrienne M. Landry-Bayle, Alice Lee-Dutra, Kelly J. McClure, Taraneh Mirzadegan, Alejandro Santillán, Jr.
  • Aryl-substituted bridged or fused diamines as modulators of leukotriene A ydrolase
    Patent number: 8344008
    Abstract: Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: January 1, 2013
    Assignee: Janssen Pharmaceutica NV
    Inventors: Genesis M. Bacani, Scott D. Bembenek, Wendy Eccles, James P. Edwards, Matthew T. Epperson, Laurent Gomez, Cheryl A. Grice, Aaron M. Kearney, Adrienne M. Landry-Bayle, Alice Lee-Dutra, Kelly J. McClure, Taraneh Mirzadegan, Alexandro Santillán, Jr.
  • Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase
    Publication number: 20110263639
    Abstract: Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.
    Type: Application
    Filed: April 21, 2011
    Publication date: October 27, 2011
    Inventors: Genesis M. Bacani, Scott D. Bembenek, Wendy Eccles, James P. Edwards, Matthew T. Epperson, Laurent Gomez, Cheryl A. Grice, Aaron M. Kearney, Adrienne M. Landry-Bayle, Alice Lee-Dutra, Kelly J. McClure, Taraneh Mirzadegan, Alejandro Santillán, JR.
  • Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase
    Publication number: 20110257153
    Abstract: Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.
    Type: Application
    Filed: April 21, 2011
    Publication date: October 20, 2011
    Inventors: Genesis M. Bacani, Scott D. Bembenek, Wendy Eccles, James P. Edwards, Matthew T. Epperson, Laurent Gomez, Cheryl A. Grice, Aaron M. Kearney, Adrienne M. Landry-Bayle, Alice Lee-Dutra, Kelly J. Mcclure, Taraneh Mirzadegan, Alexandro Santillan, JR.
  • INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR
    Publication number: 20110178062
    Abstract: Certain substituted indole and benzothiophene compounds are histamine H3 receptor modulators useful in the treatment of histamine H3 receptor-mediated diseases.
    Type: Application
    Filed: February 28, 2008
    Publication date: July 21, 2011
    Inventors: Brett D. Allison, Cheryl A. Grice, Kelly J. McClure, Alejandro Santillan, JR.
  • Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase
    Publication number: 20090111794
    Abstract: Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.
    Type: Application
    Filed: October 30, 2008
    Publication date: April 30, 2009
    Inventors: Genesis M. Bacani, Scott D. Bembenek, Wendy Eccles, James P. Edwards, Matthew T. Epperson, Laurent Gomez, Cheryl A. Grice, Aaron M. Kearney, Adrienne M. Landry-Bayle, Alice Lee-Dutra, Kelly J. McClure, Taraneh Mirzadegan, Alejandro Santillan, JR.
  • Substituted benzimidazoles and imidazo-[4,5]-pyridines
    Patent number: 7504414
    Abstract: 2-Aryl substituted benzimidazoles and imidazo[4,5]pyridines are disclosed as inhibitors of Cds1 and useful as adjuvants to chemotherapy or radiation therapy in the treatment of cancer.
    Type: Grant
    Filed: August 2, 2007
    Date of Patent: March 17, 2009
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Kristen L. Arienti, Frank U. Axe, J. Guy Breitenbucher, Liming Huang, Alice Lee, Kelly J. McClure
  • CCK-1 receptor modulators
    Patent number: 7465808
    Abstract: There are provided by the present invention certain pyrazole based CCK-1 receptor modulators.
    Type: Grant
    Filed: September 19, 2005
    Date of Patent: December 16, 2008
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Terrance D. Barrett, J. Guy Breitenbucher, Laurent Gomez, Michael D. Hack, Liming Huang, Kelly J. McClure, Magda F. Morton, Clark A. Sehon, Nigel P. Shankley
  • Substituted benzimidazoles and imidazo-[4,5]-pyridines
    Patent number: 7271261
    Abstract: 2-Aryl substituted benzimidazoles and imidazo[4,5]pyridines are disclosed as inhibitors of Cds1 and useful as adjuvants to chemotherapy or radiation therapy in the treatment of cancer.
    Type: Grant
    Filed: October 18, 2002
    Date of Patent: September 18, 2007
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Kristen L. Arienti, Frank U. Axe, J. Guy Breitenbucher, Liming Huang, Alice Lee, Kelly J. McClure
  • CCK-1 receptor modulators
    Patent number: 7037931
    Abstract: There are provided by the present invention certain pyrazole based CCK-1 receptor modulators.
    Type: Grant
    Filed: July 2, 2003
    Date of Patent: May 2, 2006
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Terrance D. Barrett, J. Guy Breitenbucher, Laurent Gomez, Michael D. Hack, Liming Huang, Kelly J. McClure, Magda F. Morton, Clark A. Sehon, Nigel P. Shankley
  • CCK-1 receptor modulators
    Publication number: 20040067983
    Abstract: There are provided by the present invention certain pyrazole based CCK-1 receptor modulators.
    Type: Application
    Filed: July 2, 2003
    Publication date: April 8, 2004
    Inventors: Terrance D. Barrett, J. Guy Breitenbucher, Laurent Gomez, Michael D. Hack, Liming Huang, Kelly J. McClure, Magda F. Morton, Clark A. Sehon, Nigel P. Shankley
  • Substituted benzimidazoles and imidazo-[4,5]-pyridines
    Publication number: 20030176438
    Abstract: 2-Aryl substituted benzimidazoles and imidazo[4,5]pyridines are disclosed as inhibitors of Cds1 and useful as adjuvants to chemotherapy or radiation therapy in the treatment of cancer.
    Type: Application
    Filed: October 18, 2002
    Publication date: September 18, 2003
    Inventors: Kristen L. Arienti, Frank U. Axe, J. Guy Breitenbucher, Liming Huang, Alice Lee, Kelly J. McClure